BioLineRx Ltd.
BLRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001498403
No open-market purchases or sales by BioLineRx Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $206.7K in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding BioLineRx Ltd. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 17 | 14 | −3 |
| Shares | 66.2K | 27.7K | −38.5K (−58.2%) |
| Value | $302.1K | $104.3K | −$197.8K (−65.5%) |
New holders (3)
Institutions that held BioLineRx Ltd. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 6,387 | $24.1K | 0.00% |
| Tower Research Capital LLC (TRC) | 39 | $147 | 0.00% |
| Rockefeller Capital Management L.P. | 12 | $45 | 0.00% |
Sold out (6)
Institutions that held BioLineRx Ltd. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Two Sigma Securities, LLC | 13,816 | $63.1K |
| Susquehanna International Group, LLP | 11,098 | $50.7K |
| Citigroup Inc | 4,005 | $18.3K |
| National Bank of Canada | 200 | $914 |
| Raymond James Financial Inc | 72 | $329 |
| Fifth Third Bancorp | 25 | $114 |